HAOHAI BIOTEC (06826) plans to acquire the remaining 20% equity interest of Shenzhen New Industries Biomedical Engineering Ophthalmic New Technology Co., Ltd. for 74 million yuan.

HAOHAI BIOTEC (06826) announced that on November 7, 2025, its wholly-owned subsidiary Shanghai Haohai Medical Technology, as the transferee, entered into a supplementary agreement for the transfer of equity with the transferor Mr. Zhang, Shenzhen Jiusi, and Shenzhen Baina, whereby the transferor agreed to sell the remaining 20% equity of the target company (ShenZhen New Industries Biomedical Engineering Ophthalmic New Technology Co., Ltd.) to the transferee for a consideration of RMB 74 million. Upon completion of the acquisition, the Group will hold 100% equity of the target company. The target company is a limited company established in China, mainly engaged in the manufacture and sale of corneal shaping lens products and artificial intraocular lens products, as well as the distribution of imported ophthalmic products such as artificial intraocular lens products, ophthalmic viscoelastic agents, and sodium hyaluronate gel for glaucoma surgery in mainland China. Since acquiring 60% and 20% equity of the target company in November 2016 and February 2023 respectively, the Group has been steadily entering the high-value ophthalmic consumables field. After years of integration and development, the Group has become a leading manufacturer of artificial intraocular lens products in China, with the target company now being one of the main subsidiaries of the company. Upon completion of the acquisition, the Group's equity in the target company will increase to 100%, beneficial for enhancing the management and operational efficiency of the target company, thereby strengthening the market competitiveness of the Group's ophthalmic products. Therefore, the directors believe that the acquisition is in line with the development needs and overall business strategy of the Group.